Gilead Sciences Inc. reported stunning interim results from its Phase II ELECTRON study of 12 weeks of therapy with investigational hepatitis C (HCV) combo sofosbuvir (GS-7977) and GS-5885 with ribavirin showing the best-possible results at four weeks after treatment, a 100 percent sustained virologic response (SVR4).